These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

869 related items for PubMed ID: 7515387

  • 1. Effects of replacement dose of dehydroepiandrosterone in men and women of advancing age.
    Morales AJ, Nolan JJ, Nelson JC, Yen SS.
    J Clin Endocrinol Metab; 1994 Jun; 78(6):1360-7. PubMed ID: 7515387
    [Abstract] [Full Text] [Related]

  • 2. Endocrine and metabolic effects of long-term administration of [Nle27]growth hormone-releasing hormone-(1-29)-NH2 in age-advanced men and women.
    Khorram O, Laughlin GA, Yen SS.
    J Clin Endocrinol Metab; 1997 May; 82(5):1472-9. PubMed ID: 9141536
    [Abstract] [Full Text] [Related]

  • 3. The effect of six months treatment with a 100 mg daily dose of dehydroepiandrosterone (DHEA) on circulating sex steroids, body composition and muscle strength in age-advanced men and women.
    Morales AJ, Haubrich RH, Hwang JY, Asakura H, Yen SS.
    Clin Endocrinol (Oxf); 1998 Oct; 49(4):421-32. PubMed ID: 9876338
    [Abstract] [Full Text] [Related]

  • 4. Dehydroepiandrosterone supplementation in women with adrenal failure: impact on twenty-four hour GH secretion and IGF-related parameters.
    Christiansen JJ, Gravholt CH, Fisker S, Svenstrup B, Bennett P, Veldhuis J, Andersen M, Christiansen JS, Jørgensen JO.
    Clin Endocrinol (Oxf); 2004 Apr; 60(4):461-9. PubMed ID: 15049961
    [Abstract] [Full Text] [Related]

  • 5. Dehydroepiandrosterone (DHEA) replacement reduces growth hormone (GH) dose requirement in female hypopituitary patients on GH replacement.
    Brooke AM, Kalingag LA, Miraki-Moud F, Camacho-Hübner C, Maher KT, Walker DM, Hinson JP, Monson JP.
    Clin Endocrinol (Oxf); 2006 Nov; 65(5):673-80. PubMed ID: 17054472
    [Abstract] [Full Text] [Related]

  • 6. Circulating levels of insulin-like growth factor (IGF) binding protein-1 and -3 in aging men: relationships to insulin, glucose, IGF, and dehydroepiandrosterone sulfate levels and anthropometric measures.
    Benbassat CA, Maki KC, Unterman TG.
    J Clin Endocrinol Metab; 1997 May; 82(5):1484-91. PubMed ID: 9141538
    [Abstract] [Full Text] [Related]

  • 7. The effects of oral dehydroepiandrosterone on endocrine-metabolic parameters in postmenopausal women.
    Mortola JF, Yen SS.
    J Clin Endocrinol Metab; 1990 Sep; 71(3):696-704. PubMed ID: 2144295
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. The insulin-like growth factor axis and plasma lipid levels in the elderly.
    Ceda GP, Dall'Aglio E, Magnacavallo A, Vargas N, Fontana V, Maggio M, Valenti G, Lee PD, Hintz RL, Hoffman AR.
    J Clin Endocrinol Metab; 1998 Feb; 83(2):499-502. PubMed ID: 9467564
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. The effect of dehydroepiandrosterone supplementation to symptomatic perimenopausal women on serum endocrine profiles, lipid parameters, and health-related quality of life.
    Barnhart KT, Freeman E, Grisso JA, Rader DJ, Sammel M, Kapoor S, Nestler JE.
    J Clin Endocrinol Metab; 1999 Nov; 84(11):3896-902. PubMed ID: 10566625
    [Abstract] [Full Text] [Related]

  • 13. Effects of GH and/or sex steroids on circulating IGF-I and IGFBPs in healthy, aged women and men.
    Münzer T, Rosen CJ, Harman SM, Pabst KM, St Clair C, Sorkin JD, Blackman MR.
    Am J Physiol Endocrinol Metab; 2006 May; 290(5):E1006-13. PubMed ID: 16390864
    [Abstract] [Full Text] [Related]

  • 14. Low dose dehydroepiandrosterone affects behavior in hypopituitary androgen-deficient women: a placebo-controlled trial.
    Johannsson G, Burman P, Wirén L, Engström BE, Nilsson AG, Ottosson M, Jonsson B, Bengtsson BA, Karlsson FA.
    J Clin Endocrinol Metab; 2002 May; 87(5):2046-52. PubMed ID: 11994339
    [Abstract] [Full Text] [Related]

  • 15. A paradoxical gender dissociation within the growth hormone/insulin-like growth factor I axis during protracted critical illness.
    Van den Berghe G, Baxter RC, Weekers F, Wouters P, Bowers CY, Veldhuis JD.
    J Clin Endocrinol Metab; 2000 Jan; 85(1):183-92. PubMed ID: 10634385
    [Abstract] [Full Text] [Related]

  • 16. Effects of oral versus transdermal estrogen on the growth hormone/insulin-like growth factor I axis in younger and older postmenopausal women: a clinical research center study.
    Bellantoni MF, Vittone J, Campfield AT, Bass KM, Harman SM, Blackman MR.
    J Clin Endocrinol Metab; 1996 Aug; 81(8):2848-53. PubMed ID: 8768841
    [Abstract] [Full Text] [Related]

  • 17. Serum insulin-like growth factor I (IGF-I), IGF-binding protein-1 and -3, and the acid-labile subunit as serum markers of body composition during growth hormone (GH) therapy in adults with GH deficiency.
    Thorén M, Hilding A, Baxter RC, Degerblad M, Wivall-Helleryd IL, Hall K.
    J Clin Endocrinol Metab; 1997 Jan; 82(1):223-8. PubMed ID: 8989263
    [Abstract] [Full Text] [Related]

  • 18. Activation of immune function by dehydroepiandrosterone (DHEA) in age-advanced men.
    Khorram O, Vu L, Yen SS.
    J Gerontol A Biol Sci Med Sci; 1997 Jan; 52(1):M1-7. PubMed ID: 9008662
    [Abstract] [Full Text] [Related]

  • 19. Mechanisms of thyroid hormone action on the insulin-like growth factor system: all thyroid hormone effects are not growth hormone mediated.
    Näntö-Salonen K, Muller HL, Hoffman AR, Vu TH, Rosenfeld RG.
    Endocrinology; 1993 Feb; 132(2):781-8. PubMed ID: 7678799
    [Abstract] [Full Text] [Related]

  • 20. The Dehydroepiandrosterone And WellNess (DAWN) study: research design and methods.
    von Mühlen D, Laughlin GA, Kritz-Silverstein D, Barrett-Connor E.
    Contemp Clin Trials; 2007 Feb; 28(2):153-68. PubMed ID: 16784898
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 44.